Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares Issued
Ratios

Kiniksa Pharmaceuticals International (KNSA) EBIAT (2021 - 2025)

Historic EBIAT for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to $18.4 million.

  • Kiniksa Pharmaceuticals International's EBIAT rose 24523.75% to $18.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.9 million, marking a year-over-year increase of 49609.62%. This contributed to the annual value of -$43.2 million for FY2024, which is 40668.13% down from last year.
  • Kiniksa Pharmaceuticals International's EBIAT amounted to $18.4 million in Q3 2025, which was up 24523.75% from $17.8 million recorded in Q2 2025.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's EBIAT peaked at $224.1 million during Q3 2022, and registered a low of -$49.5 million during Q1 2021.
  • Moreover, its 5-year median value for EBIAT was -$12.3 million (2023), whereas its average is $2.2 million.
  • As far as peak fluctuations go, Kiniksa Pharmaceuticals International's EBIAT surged by 83367.27% in 2022, and later plummeted by 13521.81% in 2024.
  • Kiniksa Pharmaceuticals International's EBIAT (Quarter) stood at -$36.3 million in 2021, then skyrocketed by 112.28% to $4.5 million in 2022, then soared by 465.73% to $25.2 million in 2023, then tumbled by 135.22% to -$8.9 million in 2024, then surged by 307.41% to $18.4 million in 2025.
  • Its last three reported values are $18.4 million in Q3 2025, $17.8 million for Q2 2025, and $8.5 million during Q1 2025.